Major Events - Sinopharm (01801) has reached a global strategic cooperation with Takeda Pharmaceutical and plans to issue shares under general authorization [1] - China Unicom (00762) intends to spin off Zhinet Technology for listing on the Shenzhen Stock Exchange's ChiNext [1] - Laopuhuangjin (06181) plans to place approximately 3.7118 million new H-shares at a discount of about 4.50%, raising approximately HKD 2.707 billion [1] - Xinyi International (00732) intends to acquire approximately 11.43% equity in Xinyi Renshou through public bidding [1] - Xuan Bamboo Biotechnology-B (02575) will present clinical phase III research data for Pyrocilin as a first-line treatment for HR+/HER2- advanced breast cancer at ESMO 2025 [1] - Jinfang Pharmaceutical-B (02595) has completed the first patient dosing in the Ib/II phase study of KRAS G12D inhibitor GFH375 in combination with cetuximab or chemotherapy for advanced solid tumors [1] - Weihua Holdings (00622) plans to sell Shengjing H-shares for HKD 503 million [1] - Huajian Medical (01931) intends to change its English name to "ETHK Labs Inc." [1] - Nohui Health (06606) will have its listing status canceled starting October 27 [1] - Akun Real Estate (06900) will have its listing status canceled starting October 27 [1] - Jianzhong Construction (00589) will have its listing status canceled starting October 27 [1] Operating Performance - China Unicom (00762) reported a net profit attributable to shareholders of RMB 20 billion for the first three quarters, an increase of 5.1% year-on-year [2] - China Railway (00390) signed new contracts worth RMB 1,584.92 billion in the first nine months, a year-on-year increase of 3.7% [2] - China Communications Construction (01800) reported new contracts of RMB 1,339.97 billion for the first three quarters, a year-on-year growth of 4.65% [2] - Cathay Pacific (00293) saw a 21% year-on-year increase in passenger volume in September [2] - Tabo (06110) reported a profit attributable to equity holders of approximately RMB 789 million for the interim period, a decrease of 9.69% year-on-year [2] - Shanghai Petrochemical (00338) reported a net loss attributable to the parent company of RMB 432 million for the first three quarters [2]
港股公告掘金 | 信达生物与武田制药达成全球战略合作及根据一般授权发行股份